Shots:
- BBOT has reported first pts dosing in its P-I (KONQUER-101) trial assessing BBO-11818 for advanced solid tumors, with trial enrolling pts globally
- In cellular assays, BBO-11818 showed pERK inhibition in selected KRAS G12D & G12V-mutant cell lines at lower concentrations, while reducing viability in KRAS G12D/G12V/G12C mutant cells & exhibiting >500-fold selectivity for KRAS over H-RAS & NRAS mutations
- BBO-11818 is an oral small-molecule dual inhibitor that binds to both “ON” & “OFF” states of KRAS, discovered via collaboration between the RAS Initiative at Frederick National Laboratory, Lawrence Livermore National Laboratory, & BBOT
Ref: BBOT | Image: BBOT
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
